期刊文献+

他汀类药物不良反应分析 被引量:3

Analysis of Adverse Drug Reactions Induced by Statins
下载PDF
导出
摘要 目的:探讨他汀类药物所致不良反应的特点及相关因素,为临床合理用药提供参考。方法:查阅《中国医院知识仓库(CHKD)全文期刊库》(1998~2008)年他汀类药物致不良反应的有关文献60篇(共66例)进行统计分析。结果:他汀类所致不良反应多发生在(51~80)岁年龄段,集中发生在给药后30天内,主要表现为肌肉毒性、肝脏毒性、过敏反应等方面。结论:临床医师和药师应重视他汀类药物的不良反应,促进其合理应用。 Objective: To provide a rational of clinical drug safety by analyzing the adverse drug reactions(ADR)caused by Statins. Methods:60 Statins-reduced ADR reports (66 cases) published in China Hospital Knowledge Database from 1998 to 2008 was analyzed statistically. Results: The ADR induced by Statins were more often occurred in patients aged from 51 to 80, usually appeared within 30 day after drug use. The clinical presentation were seen in the toxic reactions of muscle, the toxic reactions of liver, allergic, ect. Conclusion: Clinician and pharmacists should attach great importance to statin-induced ADR in clinical practice and promote its rational use.
作者 温晓娜
出处 《中国医药导刊》 2011年第1期128-129,共2页 Chinese Journal of Medicinal Guide
关键词 他汀类药物 不良反应 文献分析 Statins Adverse drug reactions Literature analysis
  • 相关文献

参考文献8

二级参考文献124

  • 1胡晓文,陆国椿,丁俊杰,孙祎.药源性肌病的临床表现及致病药物[J].药物不良反应杂志,2005,7(2):106-108. 被引量:4
  • 2张奇.他汀类药物临床应用注意点[J].临床内科杂志,2006,23(1):12-15. 被引量:8
  • 3吕瑞娟,张运,陈玉国,孙袆,王文君.他汀类药物治疗ALT升高的急性冠状动脉综合征的可行性研究[J].新医学,2006,37(6):368-369. 被引量:16
  • 4[1]Erie Bruckcrt.Epidemiology of low HDL-cholesterol:results of studies and surveys.Eur Heart J,2006,8(suppl F):F17-F22
  • 5[2]Barter PJ,Rye KA.Is there a role for Fibrates in the management of dyslipidemia in the metabolic syndrome?Arteriosclerosis,Thrombosis,and Vascular Biology,2008,28:39
  • 6[3]Singh IM,Shishehbor MH,Ansell BJ.HigII-density lipoprotein as a therapeutic target.JAMA.2007,298:786-798
  • 7[4]Heinz Drexel.Reducing risk by raising HDL-cholesterol:the evidenee.Eur Heart Journal,2006,8(Suppl F):F23-F29
  • 8[5]Barter PJ,FRACP,Rye KA.Cardioprotective properties of Fibrates.which Fibrate,which patients,what mechanism? Circulation,2006,113:1553-55
  • 9[6]Muhammad Usman,Rajesh Peter.Fibrate therapy:safety considerations.Curt Opon in Lipidology,2007,18:702-6
  • 10[7]Davidson MH,Annemaxie Armani,McKenney Jm et al.Safety considerations with Fibrate therapy.Am J Cardiol,2007,99(suppl):3C-18C

共引文献90

同被引文献33

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部